References
- Tefferi A. Myeloproliferative neoplasms: a decade of discoveries and treatment advances. Am J Hematol. 2016;91(1):50–58.
- Spivak JL. Myeloproliferative neoplasms. N Engl J Med. 2017;376(22):2168–2181.
- Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379–2390.
- Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391–2405.
- Al Assaf C, Van Obbergh F, Billiet J, et al. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations. Haematologica. 2015;100(7):893–897.
- Rumi E, Pietra D, Pascutto C, Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014;124(7):1062–1069.
- Ojeda MJ, Bragós IM, Calvo KL, et al. CALR, JAK2 and MPL mutation status in argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms. Hematology. 2018;23(4):208–211.
- Cordua S, Kjaer L, Skov V, et al. Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a danish general population. Blood. 2019;134(5):469–479.
- Sun C, Zhou X, Zou ZJ, et al. Clinical manifestation of calreticulin gene mutations in essential thrombocythemia without janus kinase 2 and MPL mutations: a chinese cohort clinical study. Chin Med J. 2016;129(15):1778–1783.
- Rumi E, Pietra D, Ferretti V, Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544–1551.
- Tefferi A, Nicolosi M, Mudireddy M, et al. Driver mutations and prognosis in primary myelofibrosis: mayo-Careggi MPN alliance study of 1,095 patients. Am J Hematol. 2018;93(3):348–355.
- Grinfeld J, Nangalia J, Baxter EJ, et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018;379(15):1416–1430.
- Venugopal S, Mascarenhas J. Novel therapeutics in myeloproliferative neoplasms. J Hematol Oncol. 2020;13(1):162.
- Larsen TS, Christensen JH, Hasselbalch HC, et al. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol. 2007;136(5):745–751.
- Almedal H, Vorland M, Aarsand AK, et al. Myeloproliferative neoplasms and JAK2 mutations. J Nor Med Ass. 2016;136(22):1889–1894.
- Pietra D, Rumi E, Ferretti VV, et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia. 2016;30(2):431–438.
- Pedersen KM, Bak M, Sørensen AL, et al. Smoking is associated with increased risk of myeloproliferative neoplasms: a general population-based cohort study. Cancer Med. 2018;7(11):5796–5802.
- Lindholm Sørensen A, Hasselbalch HC. Smoking and philadelphia-negative chronic myeloproliferative neoplasms. Eur J Haematol. 2016;97(1):63–69.
- Jayasuriya NA, Kjaergaard AD, Pedersen KM, et al. Smoking, blood cells and myeloproliferative neoplasms: meta-analysis and Mendelian randomization of 2·3 million people. Br J Haematol. 2020;189(2):323–334.